Existing chemotherapy regimes are largely ineffective against advanced stages of cervical cancer, which kills 250,000 women worldwide every year.
That’s why early screening is so critical — regular Pap smears have managed to reduce deaths in wealthy countries by 80 percent.
The study found that women who were given the drug bevacizumab (Avastin) along with their chemotherapy prolonged survival to an average of 17 months, compared with 13.3 months for those who only received chemotherapy.
Tumor shrinkage rates were 48 percent for patients who received the drug, compared with 36 percent for those who did not.
The results also indicated that the survival benefit did not come at the cost of diminished quality of life.
The phase III clinical trial separated the 452 patients into four treatment arms but found no significant differences in survival between those receiving cisplatin or topotecan (Hycamtin) chemotherapy treatments.
Genentech’s drug bevacizumab is currently approved by US regulators for use in several advanced cancers but has not yet been approved for gynecological cancer. It works to block blood vessel formation in the tumor.
Some 4,000 women die of cervical cancer every year in the United States.
No comments:
Post a Comment